Latest RA CAPITAL MANAGEMENT, L.P. Stock Portfolio
RA CAPITAL MANAGEMENT, L.P. Performance:
2025 Q1: -20.9%YTD: -20.9%2024: 4.04%
Performance for 2025 Q1 is -20.9%, and YTD is -20.9%, and 2024 is 4.04%.
About RA CAPITAL MANAGEMENT, L.P. and 13F Hedge Fund Stock Holdings
RA CAPITAL MANAGEMENT, L.P. is a hedge fund based in BOSTON, MA. On 03-Apr-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $9.7 Billions. In it's latest 13F Holdings report, RA CAPITAL MANAGEMENT, L.P. reported an equity portfolio of $6 Billions as of 31 Mar, 2025.
The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are , PCVX, RYTM. The fund has invested 26.8% of it's portfolio in ASCENDIS PHARMA A/S - ADR and 7.7% of portfolio in VAXCYTE INC.
The fund managers got completely rid off LEGEND BIOTECH CORP-ADR, SPDR S&P BIOTECH ETF (BIL) and AXSOME THERAPEUTICS INC (AXSM) stocks. They significantly reduced their stock positions in BRIGHT MINDS BIOSCIENCES INC, 10X GENOMICS INC-CLASS A (TXG) and KURA ONCOLOGY INC (KURA). RA CAPITAL MANAGEMENT, L.P. opened new stock positions in SIONNA THERAPEUTICS INC, UROGEN PHARMA LTD (URGN) and GLAUKOS CORP (GKOS). The fund showed a lot of confidence in some stocks as they added substantially to SCHOLAR ROCK HOLDING CORP (SRRK), SURROZEN INC (SRZN) and GERON CORP (GERN).
The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are , PCVX, RYTM. The fund has invested 26.8% of it's portfolio in ASCENDIS PHARMA A/S - ADR and 7.7% of portfolio in VAXCYTE INC.
The fund managers got completely rid off LEGEND BIOTECH CORP-ADR, SPDR S&P BIOTECH ETF (BIL) and AXSOME THERAPEUTICS INC (AXSM) stocks. They significantly reduced their stock positions in BRIGHT MINDS BIOSCIENCES INC, 10X GENOMICS INC-CLASS A (TXG) and KURA ONCOLOGY INC (KURA). RA CAPITAL MANAGEMENT, L.P. opened new stock positions in SIONNA THERAPEUTICS INC, UROGEN PHARMA LTD (URGN) and GLAUKOS CORP (GKOS). The fund showed a lot of confidence in some stocks as they added substantially to SCHOLAR ROCK HOLDING CORP (SRRK), SURROZEN INC (SRZN) and GERON CORP (GERN).
RA CAPITAL MANAGEMENT, L.P. Annual Return Estimates Vs S&P 500
Our best estimate is that RA CAPITAL MANAGEMENT, L.P. made a return of -20.9% in the last quarter. In trailing 12 months, it's portfolio return was -27.25%.
New Buys
| Ticker | $ Bought |
|---|---|
| sionna therapeutics inc | 109,258,000 |
| disc medicine inc | 78,287,500 |
| urogen pharma ltd | 35,461,400 |
| glaukos corp | 18,725,000 |
| metsera inc | 18,387,800 |
| arcus biosciences inc | 8,920,460 |
| acadia healthcare co inc | 6,579,440 |
| beta bionics inc | 6,120,000 |
New stocks bought by RA CAPITAL MANAGEMENT, L.P.
Additions
| Ticker | % Inc. |
|---|---|
| scholar rock holding corp | 6,351 |
| surrozen inc | 140 |
| geron corp | 101 |
| iteos therapeutics inc | 74.41 |
| dianthus therapeutics inc | 53.6 |
| dyne therapeutics inc | 52.24 |
| 89bio inc | 40.31 |
| vaxcyte inc | 40.28 |
Additions to existing portfolio by RA CAPITAL MANAGEMENT, L.P.
Reductions
| Ticker | % Reduced |
|---|---|
| bright minds biosciences inc | -55.21 |
| 10x genomics inc-class a | -40.71 |
| bioage labs inc | -19.69 |
| kura oncology inc | -10.03 |
RA CAPITAL MANAGEMENT, L.P. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| chimerix inc | -30,624,000 |
| recursion pharmaceuticals-a | -52,221,600 |
| legend biotech corp-adr | -244,276,000 |
| c4 therapeutics inc | -17,560,800 |
| evolent health inc - a | -40,243,500 |
| verona pharma plc - adr | -82,051,600 |
| pliant therapeutics inc | -16,870,800 |
| spdr s&p biotech etf | -110,615,000 |
RA CAPITAL MANAGEMENT, L.P. got rid off the above stocks
Sector Distribution
RA CAPITAL MANAGEMENT, L.P. has about 55.5% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 55.5 |
| Others | 42.2 |
| 2.3 |
Market Cap. Distribution
RA CAPITAL MANAGEMENT, L.P. has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 45.8 |
| MID-CAP | 28.9 |
| SMALL-CAP | 20.5 |
| MICRO-CAP | 2.5 |
| NANO-CAP | 1.2 |
Stocks belong to which Index?
About 47% of the stocks held by RA CAPITAL MANAGEMENT, L.P. either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 53 |
| RUSSELL 2000 | 47 |
RA CAPITAL MANAGEMENT, L.P. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P. has 85 stocks in it's portfolio. About 62.9% of the portfolio is in top 10 stocks. PCVX proved to be the most loss making stock for the portfolio. SBTX was the most profitable stock for RA CAPITAL MANAGEMENT, L.P. last quarter.
Last Reported on: 15 May, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABOS | acumen pharmaceuticals inc | 0.27 | 14,932,100 | 16,425,300 | unchanged | 0.00 | ||
| ACET | adicet bio inc | 0.10 | 7,541,000 | 5,693,460 | unchanged | 0.00 | ||
| ACHC | acadia healthcare co inc | 0.11 | 217,000 | 6,579,440 | new | |||
| ACLX | arcellx inc | 3.33 | 3,036,530 | 199,196,000 | added | 8.94 | ||
| ACRS | aclaris therapeutics inc | 0.12 | 4,666,670 | 7,140,000 | unchanged | 0.00 | ||
| ALEC | alector inc | 0.20 | 9,695,230 | 11,925,100 | unchanged | 0.00 | ||
| ALLK | allakos inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARVN | arvinas inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ATXS | astria therapeutics inc | 0.46 | 5,105,210 | 27,261,800 | unchanged | 0.00 | ||
| AVTE | aerovate therapeutics inc | 0.38 | 262,631 | 23,072,200 | unchanged | 0.00 | ||
| AVTX | avalo therapeutics inc | 0.13 | 967,000 | 7,745,670 | unchanged | 0.00 | ||
| AXSM | axsome therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BCYC | bicycle therapeutics plc-adr | 0.16 | 1,093,480 | 9,283,620 | unchanged | 0.00 | ||
| BIL | spdr s&p biotech etf | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CCCC | c4 therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CDTX | cidara therapeutics inc | 0.39 | 1,092,800 | 23,538,800 | unchanged | 0.00 | ||
| CMRX | chimerix inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CTMX | cytomx therapeutics inc | 0.01 | 1,000,000 | 635,800 | new | |||
| DAWN | day one biopharmaceuticals i | 0.76 | 5,755,580 | 45,641,700 | unchanged | 0.00 | ||
| DYN | dyne therapeutics inc | 1.70 | 9,714,390 | 101,613,000 | added | 52.24 | ||